Thomas Nelius was born in Aschersleben, Germany, in 1967. He received the Medical Degree and Doctor of Philosophy from the University Halle/Wittenberg, Germany in 1994 and 1995, respectively. He completed his Residency in Urology at a Teaching Hospital of the Otto-von-Guericke University Magdeburg, Germany and at the Princess of Wales Hospital, Bridgend, United Kingdom from 1994-2000. He is Board Certified by the German Board of Urology. From 2001-2003, he was a Research Associate of the Department of Urology at Northwestern University Chicago, IL, USA, where he worked on the development of new anti-angiogenic treatment strategies. Presently, he is an Associate Professor in the Department of Urology at Texas Tech University Health Sciences Center, Lubbock, TX, USA. His area of expertise includes also treatment of urological malignancies. He is mainly interested in new treatment strategies for prostate cancer, including e.g. anti-angiogenic strategies and metronomic chemotherapy in patients with hormone-refractory prostate cancer. He is an active reviewer for multiple Medical Journals and and member of the American Urological Association, German Society of Urology, South Central Section of the American Urological Association, American Society of Clinical Oncology, American Association of Cancer Research and Southwest Oncology Group Affiliate Program.